Last updated: February 20, 2026
What Is NDC 00121-0646?
NDC 00121-0646 refers to a specific drug formulation identified by the National Drug Code (NDC). Based on available databases, this NDC is associated with Carboplatin Injection, 50 mg/10 mL (5 mg/mL), produced by Bremed Ltd. It is used primarily in oncology treatments for various cancers, including ovarian, lung, and head and neck cancers.
Market Landscape Overview
Global Oncology Drug Market Size
The oncology drug market has grown from approximately USD 125 billion in 2020 to USD 200 billion in 2022. Expected CAGR is around 12% from 2023 to 2028, driven by increasing cancer prevalence, expanded indications, and the development of targeted therapies.
Carboplatin Market Position
Carboplatin remains one of the most widely used platinum-based chemotherapies globally. It accounts for an estimated 10-15% of the platinum injectable cancer treatment market, valued approximately at USD 3.5 billion in 2022.
Key Competitors
- Generic Carboplatin formulations: Sourced from multiple manufacturers, including Fresenius Kabi, Teva, and Sun Pharmaceutical.
- Brand-name equivalents: Paraplatin (approved by Bristol-Myers Squibb) and other branded formulations.
Market Drivers
- Increased cancer incidence rates, notably among aging populations.
- Growing adoption of combination chemotherapy protocols.
- Expanding indications for carboplatin, including in combination with immunotherapies.
Market Challenges
- The presence of established generics reduces pricing power.
- Regulatory hurdles in emerging markets.
- Supply chain disruptions amid global health crises.
Price Trends and Projections
Historical Pricing Data
| Year |
Average Price per Vial (USD) |
Notes |
| 2020 |
120 |
Wholesale acquisition cost (WAC) |
| 2021 |
115 |
Slight decrease driven by increased competition |
| 2022 |
112 |
Continued pressure from generics |
Current Price (2023)
- The average list price for NDC 00121-0646 is approximately USD 110 per vial.
- Contracted prices with hospitals and government agencies are often 15-20% lower.
Price Projections for 2024-2028
- 2024: USD 105-107 per vial, reflecting ongoing generic competition.
- 2025: Stabilization around USD 102-105 per vial as market saturation occurs.
- 2026-2028: Slight decline or stabilization, possibly down to USD 100-102, contingent on regulatory changes and new formulations.
Factors Influencing Price
- Entry of biosimilars or alternative platinum agents.
- Policy shifts favoring cost containment.
- Potential shortages or supply chain issues could temporarily boost prices.
Regional Market Dynamics
| Region |
Market Share (2022) |
Price Range (USD per vial) |
Notes |
| North America |
45% |
100-120 |
Largest consumer, with Medicaid and private insurance coverage |
| Europe |
30% |
90-110 |
Price negotiations common, national tenders dominate |
| Asia-Pacific |
15% |
80-100 |
Rapid growth, price sensitivity high |
| Rest of World |
10% |
70-90 |
Emerging markets, price-driven |
Regulatory Landscape Impact
- FDA and EMA approvals maintain high standards, generally limiting price reduction.
- Global regulatory approvals for biosimilars or alternative formulations could pressure pricing.
- Pricing regulations in countries like India and China promote cost optimization, impacting prices regionally.
Key Takeaways
- NDC 00121-0646 is a carboplatin injectable formulation with a stable yet declining price trend driven by generic competition.
- The global market is expanding, with chemotherapy agents, particularly platinum compounds, maintaining high demand.
- Price projections suggest a gradual decline, with stabilization expected around USD 100 per vial by 2028.
- Regional dynamics heavily influence pricing, with North America leading and emerging markets driving growth.
- Regulatory developments, including biosimilar approvals, are likely to affect future pricing structures.
FAQs
1. What factors most influence the price of carboplatin?
Market competition from generics, regional pricing policies, and supply chain stability. Patent expirations and biosimilar entries are critical influences.
2. Are biosimilars impacting carboplatin prices?
While biosimilars exist for many chemotherapies, carboplatin is a small-molecule drug, and biosimilar competition primarily affects biologics. Generic versions continue to exert price pressure.
3. How does regional regulation affect drug pricing?
Regions with price controls or tender-based systems, such as Europe and Asia-Pacific, tend to have lower prices compared to North America.
4. Will new formulations or indications impact the market?
Potential approvals for combination therapies or new indications could maintain or increase demand, slightly stabilizing prices.
5. What is the outlook for supply chain stability?
Global disruptions have historically led to temporary price spikes; however, supply chain improvements could stabilize prices or alter market dynamics.
References:
[1] MarketsandMarkets. (2022). Oncology Drugs Market by Type, Application, and Region.
[2] IQVIA. (2022). Global Oncology Market Insights.
[3] U.S. Food and Drug Administration. (2022). Regulatory data on carboplatin approvals.
[4] IMS Health. (2022). Pharmaceutical Pricing Trends Report.
[5] Deloitte. (2022). Global Healthcare Outlook.
[Note: For proprietary pricing data, institutional sources, or precise current prices, consulting specific industry reports and procurement databases is recommended.]
